Prognia
Drug Database
🇪🇺EU · EMAWithdrawnATC: C09XA02

Enviage(aliskiren)

Hypertension

Marketing Authorisation Holder: Novartis Europharm Ltd.

EMA Authorisation: 22/08/2007

INN: aliskiren

Indication

Treatment of essential hypertension

Official EMA Resources

View on EMA (ema.europa.eu)

AI Drug & Interaction Analysis

Free account required

Ask Prognia AI about Enviage — dosing recommendations, drug interactions, and current guideline evidence from ESC, EMA, NICE and more.

Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.